Kidney Cancer Clinical Trial

Feasibility of a Smart-Phone App for Patients With Advanced Renal Cell Carcinoma Undergoing Combination Immunotherapy

Summary

The purpose of the study is to test and understand acceptability and preliminary effectiveness of a mobile educational app specifically customized to patients with advanced Renal Cell Carcinoma (RCC) receiving therapy with combination immunotherapy.

View Eligibility Criteria

Eligibility Criteria

Inclusion Criteria:

Patients with Stage IV Renal Cell Carcinoma
Within 3 weeks from starting combination immune checkpoint blockade with tyrosine kinase inhibitor or multikinase inhibitor
Estimated survival of 6 months or more
Able to read and speak English

Exclusion Criteria:

Unable to read or speak English
Enrolled in another clinical trial

Study is for people with:

Kidney Cancer

Estimated Enrollment:

20

Study ID:

NCT05579847

Recruitment Status:

Active, not recruiting

Sponsor:

H. Lee Moffitt Cancer Center and Research Institute

Check Your Eligibility

Let’s see if you might be eligible for this study.

What is your age and gender ?

Submit

There is 1 Location for this study

See Locations Near You

Moffitt Cancer Center
Tampa Florida, 33612, United States

How clear is this clinincal trial information?

Study is for people with:

Kidney Cancer

Estimated Enrollment:

20

Study ID:

NCT05579847

Recruitment Status:

Active, not recruiting

Sponsor:


H. Lee Moffitt Cancer Center and Research Institute

How clear is this clinincal trial information?

×

Introducing, the Journey Bar

Use this bar to access information about the steps in your cancer journey.

Please confirm you are a US based health care provider:

Yes, I am a health care Provider No, I am not a health care provider